3Indexed trials
drug · Product Intelligence
Fingolimod
Pipeline Intelligence
Fingolimod: 3 indexed trials, 3 sponsors; 3 linked Orange Book patents and 20 FDA-linked events where matched.
3Sponsors
3Orange Book patent links
20FDA-linked events
Development evidence
NCT02325440University Hospital Muenster · multiple_sclerosisPHASE4
NCT05123703Hoffmann-La Roche · multiple_sclerosisPHASE3
NCT07483632Biogen · multiple_sclerosisPHASE3
FDA / patent evidence
10555902TASCENSO ODT · app 2149622036-01-19
10925829TASCENSO ODT · app 2149622036-01-19
9925138TASCENSO ODT · app 2149622036-01-19
Regulatory context
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2026-04-24
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2024-02-28
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2023-12-06
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2023-05-24
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2022-09-07
FDA_APPROVALTASCENSO ODT · 2021-12-23
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2021-11-12
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2021-11-10
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2021-03-05
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2021-01-19
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2020-12-30
FDA_APPROVALFINGOLIMOD HYDROCHLORIDE · 2020-12-18
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.